Clinical Trials Logo

Clinical Trial Summary

Existing guidelines recommend a duration of antibiotic treatment of endocarditis of 4-6 weeks with one or two types of intravenously administered antibiotics. The long hospitalization increases several risks for the patient, including mental strain and increased loss of function. Furthermore, it poses a significant burden on health systems. Current guidelines fail to use available data collected from patients (echo, temperature, CRP, leukocytes, procalcitonin etc.) to determine duration of treatment. A strategy including these data in treatment algorithms ensures an individualized treatment, targeting the patient's course and response to treatment. Thus, the purpose of this open-label, prospective, non-inferiority, RCT study is to investigate the safety and effectiveness of shortening treatment of endocarditis based on the individual patient's initial treatment response, sampling 750 patients, approx. 200 patients with each type of bacteria (Streptococci; Enterococcus faecalis; Staphylococcus aureus). Interim analysis will be conducted when 150 patients have been included, to assess the frequency of the event rate and inclusion rate in order to adjust the intended size of the study population.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03851575
Study type Interventional
Source Rigshospitalet, Denmark
Contact Kasper K Iversen, MD
Phone +4528712753
Email kasper.k.iversen@gmail.com
Status Recruiting
Phase N/A
Start date January 17, 2019
Completion date December 10, 2023

See also
  Status Clinical Trial Phase
Completed NCT05530837 - Characterization of Enterococcus Faecalis Endocarditis and Impact of Amoxicillin MIC Elevation on Patient Outcome
Recruiting NCT02252900 - Long-term Clinico-radiological Evolution of Patients With Brain Lesions During Infectious Endocarditis N/A
Recruiting NCT04691440 - Hyperbaric Oxygen Treatment in Humans With Gram Positive Cocci Endocarditis Phase 2
Completed NCT03681431 - Evaluation of an Antibiotic Regimen Pharmacokinetic Applicable to Enterococcus Faecalis Infective Endocarditis Phase 2